Galapagos has pulled the plug on its investigational ulcerative colitis drug GLPG1205 after it failed to hit targets in a mid-stage trial.

While the ORIGIN Phase IIa study confirmed “good pharmacokinetics, safety and tolerability” for the drug, efficacy endpoints were not met. 

Results showed that GLPG1205 did not statistically significantly differentiate from placebo on (partial) Mayo scores (a measure of disease activity), the Belgian biotech reported.

Clinical development of the drug will be discontinued in ulcerative colitis, and its future in other indications remains undecided at this point.

Ulcerative colitis is a chronic and relapsing condition characterised by unpredictable symptoms such as urgent diarrhoea, rectal bleeding and extreme fatigue, which can significantly affect quality of life.